Biologics for Allergic Disease
Keywords:
biologics monoclonal antibody, allergic disease, asthma; chronic urticaria, atopic dermatitis, chronic rhinosinusitisAbstract
Biologics are drugs made from biological products and created by biotechnology. Monoclonal antibody drugs are biological drugs that mechanisms directly to the molecular level such as cytokines or immunoglobulins. Monoclonal antibodies are a very effective treatment in cancer disease, autoimmune disease, diabetes mellitus, and allergic diseases such as Asthma, Chronic urticaria, Atopic dermatitis, and Chronic rhinosinusitis. Monoclonal antibody drugs have become the new drugs of choice for the treatment of patients who have not responded to standard treatment. This article presents to understand the biopharmaceutical production process especially monoclonal antibodies, which from the beginning, aims to explain the structure of monoclonal antibodies, their mechanism of action, the immune response of drugs, dosage, drug administration, and how to use them in the treatment of allergies, including Asthma, Chronic urticaria, Atopic dermatitis, and Chronic rhinosinusitis. In the future, who will choose more monoclonal antibody drugs for treatment to match individual or personalized medicine by the particular biological level measurement. Although these medications are expensive, biosimilar drugs have been produced. Biosimilar drugs are replicated from biological drugs, but cheaper than biological drugs. There fore, in the future, the widespread use of monoclonal antibody drugs will increase and learning the mechanism of the action mentioned in this article will make it worthwhile.
References
Eichbaum C, Haefeli WE. Biologics - nomenclature and classification. Ther Umsch 2011;68:593-601.
Posner J, Barrington P, Brier T, Datta-Mannan A. Monoclonal antibodies: Past, present and future. Handb Exp Pharmacol 2019;260:81-141.
Hanack K, Messerschmidt K, Listek M. Antibodies and selection of monoclonal antibodies. Adv Exp Med Biol 2016;917:11-22.
Leavy O. The birth of monoclonal antibodies. Nature Immunology 2016;17:S13-S.
Packer D. The history of the antibody as a tool. Acta Histochem 2021;123:151710.
Buss NA, Henderson SJ, McFarlane M, et al. Monoclonal antibody therapeutics: History and future. Curr Opin Pharmacol 2012;12:615-22.
Mayrhofer P, Kunert R. Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives. Hum Antibodies 2019;27:37-51.
Robertson JS, Chui WK, Genazzani AA, et al. The INN global nomenclature of biological medicines: A continuous challenge. Biologicals 2019;60:15-23.
Balocco R, De Sousa Guimaraes Koch S, Thorpe R, et al. New INN nomenclature for monoclonal antibodies. Lancet 2022;399:24.
Akdis CA, Arkwright PD, Brüggen MC, et al. Type 2 immunity in the skin and lungs. Allergy 2020;75:1582-605.
Divekar R, Kita H. Recent advances in epithelium-derived cytokines (IL-33, IL-25, and thymic stromal lymphopoietin) and allergic inflammation. Curr Opin Allergy Clin Immunol 2015;15:98-103.
Morita H, Matsumoto K, Saito H. Biologics for allergic and immunologic diseases. J Allergy Clin Immunol 2022;150:766-77.
Shamji MH, Valenta R, Jardetzky T, et al. The role of allergen-specific IgE, IgG and IgA in allergic disease. Allergy 2021;76:3627-41.
Lamiable O, Mayer JU, Munoz-Erazo L, et al. Dendritic cells in Th2 immune responses and allergic sensitization. Immunol Cell Biol 2020;98:807-18.
Oboki K, Ohno T, Saito H, Nakae S. Th17 and allergy. Allergol Int 2008;57:121-34.
Reddel HK, Bacharier LB, Bateman ED, et al. Global initiative for asthma strategy 2021: Executive summary and rationale for key changes. Respirology 2022;27:14-35.
Saco T, Ugalde IC, Cardet JC, et al. Strategies for choosing a biologic for your patient with allergy or asthma. Ann Allergy Asthma Immunol 2021;127:627-37.
Agache I, Akdis CA, Akdis M, et al. EAACI biologicals guidelines-recommendations for severe asthma. Allergy 2021;76:14-44.
McGregor MC, Krings JG, Nair P, et al. Role of biologics in asthma. Am J Respir Crit Care Med 2019;199:433-45.
Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198-207.
Castro M, Zangrilli J, Wechsler ME. Corrections. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015;3:e15.
Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β(2)-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016;388:2115-27.
Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018;378:2475-85.
Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol 2019;56:219-33.
Harb H, Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy 2020;50:5-14.
Zuberbier T, Abdul Latiff AH, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2022;77:734-66.
Tuchinda P. Thai clinical practice guideline for diagnosis and management of urticaria. Asian Pac J Allergy Immunol 2016;34.
Kulthanan K, Tuchinda P, Nitiyarom R, et al. Clinical practice guidelines for the diagnosis and management of atopic dermatitis. Asian Pac J Allergy Immunol 2021;39:145-55.
Seegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol 2018;11:467-74.
Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc 2019;40:84-92.
Agache I, Eguiluz-Gracia I, Cojanu C, et al. Advances and highlights in asthma in 2021. Allergy 2021;76:3390-407.
Salter B, Lacy P, Mukherjee M. Biologics in asthma: A molecular perspective to precision medicine. Front Pharmacol 2021;12:793409.
Pavord ID, Hanania NA, Corren J. Controversies in allergy: Choosing a biologic for patients with severe asthma. J Allergy Clin Immunol Pract 2022;10:410-9.
Cai S, Xu S, Lou H, et al. Comparison of different biologics for treating chronic rhinosinusitis with nasal polyps: A network analysis. J Allergy Clin Immunol Pract 2022;10:1876-86.e7.
Geng B, Dilley M, Anterasian C. Biologic therapies for allergic rhinitis and nasal polyposis. Curr Allergy Asthma Rep 2021;21:36.
Arasi S, Mennini M, Cafarotti A, et al. Omalizumab as monotherapy for food allergy. Curr Opin Allergy Clin Immunol 2021;21:286-91.
Fiocchi A, Vickery BP, Wood RA. The use of biologics in food allergy. Clin Exp Allergy 2021;51:1006-18.
Hoy SM. Tezepelumab: First approval. Drugs 2022;82:461-8.
Maurer M, Giménez-Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med 2019;381:1321-32.
Ruzicka T, Mihara R. Anti-Interleukin-31 receptor: A antibody for atopic dermatitis. N Engl J Med 2017;376:2093.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
